Irene Rodriguez-Hernandez1, Sandra Perdomo2, Angel Santos-Briz3, Juan Luis Garcia4, Juan Antonio Gomez-Moreta5, Juan Jesus Cruz6, Rogelio Gonzalez-Sarmiento7. 1. Molecular Medicine Unit, Department of Medicine, University of Salamanca, Salamanca, Spain; IBMCC and IBSAL (USAL/CSIC/University Hospital), Salamanca, Spain. 2. IINGM El Bosque University, Bogota, Colombia. 3. IBMCC and IBSAL (USAL/CSIC/University Hospital), Salamanca, Spain; Department of Pathology, University Hospital of Salamanca, Salamanca, Spain. 4. IBMCC and IBSAL (USAL/CSIC/University Hospital), Salamanca, Spain; Institute for Health Science Studies of Castilla y Leon, Salamanca, Spain. 5. Department of Neurosurgery, University Hospital of Salamanca, Salamanca, Spain. 6. IBMCC and IBSAL (USAL/CSIC/University Hospital), Salamanca, Spain; Department of Oncology, University Hospital of Salamanca, Salamanca, Spain. 7. Molecular Medicine Unit, Department of Medicine, University of Salamanca, Salamanca, Spain; IBMCC and IBSAL (USAL/CSIC/University Hospital), Salamanca, Spain. Electronic address: gonzalez@usal.es.
Abstract
BACKGROUND: Glioblastoma is the most common and aggressive primary brain tumor in adults. Despite several factors such as ionizing radiation exposure or rare genetic syndromes have been associated with the development of glioblastoma, no underlying cause has been identified for the majority of cases. We thus aimed to investigate the role of DNA repair polymorphisms in modulating glioblastoma risk. METHODS: Genotypic and allelic frequencies of seven common polymorphisms in DNA repair genes involved in nucleotide excision repair (ERCC1 rs11615, ERCC2 rs13181, ERCC6 rs4253079), base excision repair (APEX1 rs1130409, XRCC1 rs25487), double-strand break repair (XRCC3 rs861539) and mismatch repair (MLH1 rs1800734) pathways were analyzed in 115 glioblastoma patients and 200 healthy controls. Haplotype analysis was also performed for ERCC1 rs11615 and ERCC2 rs13181 polymorphisms, located on the same chromosomal region (19q13.32). RESULTS: Our results indicated that carriers of the ERCC2 Gln/Gln genotype were associated with a lower glioblastoma risk (OR=0.32, 95% CI 0.12-0.89; P=0.028), whereas carriers of the MLH1 AA genotype were associated with an increased risk of glioblastoma (OR=3.14, 95% CI 1.09-9.06; P=0.034). Furthermore, the haplotype containing the C allele of ERCC2 rs13181 polymorphism and the T allele of ERCC1 rs11615 polymorphism was significantly associated with a protective effect of developing glioblastoma (OR=0.34, 95% CI 0.16-0.71; P=0.004). CONCLUSIONS: These results pointed out that MLH1 rs1800734 and ERCC2 rs13181 polymorphisms might constitute glioblastoma susceptibility factors, and also suggested that the chromosomal region 19q could be important in glioblastoma pathogenesis.
BACKGROUND:Glioblastoma is the most common and aggressive primary brain tumor in adults. Despite several factors such as ionizing radiation exposure or rare genetic syndromes have been associated with the development of glioblastoma, no underlying cause has been identified for the majority of cases. We thus aimed to investigate the role of DNA repair polymorphisms in modulating glioblastoma risk. METHODS: Genotypic and allelic frequencies of seven common polymorphisms in DNA repair genes involved in nucleotide excision repair (ERCC1rs11615, ERCC2rs13181, ERCC6rs4253079), base excision repair (APEX1rs1130409, XRCC1rs25487), double-strand break repair (XRCC3rs861539) and mismatch repair (MLH1rs1800734) pathways were analyzed in 115 glioblastomapatients and 200 healthy controls. Haplotype analysis was also performed for ERCC1rs11615 and ERCC2rs13181 polymorphisms, located on the same chromosomal region (19q13.32). RESULTS: Our results indicated that carriers of the ERCC2Gln/Gln genotype were associated with a lower glioblastoma risk (OR=0.32, 95% CI 0.12-0.89; P=0.028), whereas carriers of the MLH1 AA genotype were associated with an increased risk of glioblastoma (OR=3.14, 95% CI 1.09-9.06; P=0.034). Furthermore, the haplotype containing the C allele of ERCC2rs13181 polymorphism and the T allele of ERCC1rs11615 polymorphism was significantly associated with a protective effect of developing glioblastoma (OR=0.34, 95% CI 0.16-0.71; P=0.004). CONCLUSIONS: These results pointed out that MLH1rs1800734 and ERCC2rs13181 polymorphisms might constitute glioblastoma susceptibility factors, and also suggested that the chromosomal region 19q could be important in glioblastoma pathogenesis.
Authors: Xuexia Wang; Can-Lan Sun; Lindsey Hageman; Kandice Smith; Purnima Singh; Sunil Desai; Douglas S Hawkins; Melissa M Hudson; Leo Mascarenhas; Joseph P Neglia; Kevin C Oeffinger; A Kim Ritchey; Leslie L Robison; Doojduen Villaluna; Wendy Landier; Smita Bhatia Journal: J Clin Oncol Date: 2017-10-04 Impact factor: 44.544